More News of Interest

Helius Medical Technologies Receives Two Medical Method Patents

April 17, 2017

Helius Medical Technologies, Inc. (TSX: HSM, HSM.S and HSM.WT.S and OTCQB: HSDT) (“Helius” or the “Company”) announced today that it has been issued two medical method patents (U.S. Patent Nos. 5,597,501 and 5,597,504) that together further protect the intellectual property rights for its core asset, the PoNS™ device therapeutic techniques.

Helius Medical Technologies advises these patents bolster the current family of PoNS patents protecting various forms of physical and cognitive therapy combinations with both skin and oral cavity stimulation using the PoNS device or any equivalent neurostimulation device.

Helius Medical Technologies has now been issued or has allowed 40 US and international patents covering the medical method, design and device features associated with the PoNS device therapy.

“Further strengthening our intellectual property with these two new medical method patents is a very meaningful development for the company. I would like to thank the team at Proskauer Rose LLP for their invaluable support and effort in helping us secure our sizable patent portfolio,” said company CEO, Philippe Deschamps.

About PoNS™ Therapy

The Portable Neuromodulation Stimulator (PoNS™) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS™ Therapy combines the use of the device with physical or cognitive therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury.


Latest Posts

Don't Miss